Close

Can-Fite (CANF) Reaches Agreement with EMA on Design of Pivotal Piclidenoson Phase 3 as Psoriasis Treatment

Go back to Can-Fite (CANF) Reaches Agreement with EMA on Design of Pivotal Piclidenoson Phase 3 as Psoriasis Treatment